Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. - Wikidata - awgldk - TriplyDB

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

http://www.wikidata.org/entity/Q27852408

about

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer Crizotinib: from discovery to accelerated development to front-line treatment Targeted therapies and immunotherapy in non-small-cell lung cancer The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer New targeted treatments for non-small-cell lung cancer - role of nivolumab Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives The role of pembrolizumab in the treatment of advanced non-small cell lung cancer Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer Afatinib in Non-Small Cell Lung Cancer Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance New strategies in immunotherapy for non-small cell lung cancer Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies Treatment of advanced squamous cell carcinoma of the lung: a review Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Lung cancer biomarkers, targeted therapies and clinical assays China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?The distinctive nature of adenocarcinoma of the lung Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses Novel targeted agents for the treatment of lung cancer in China The Evolution of Therapies in Non-Small Cell Lung Cancer Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges Predictive biomarkers in precision medicine and drug development against lung cancer

P2860

5777eb2e4c564e2e0cf7433004341e4326970856 d8894d09b94384c7e56391f96cf9882898b79fe7

P248

Q21132357-3006D3E0-20E1-4B73-B17A-49006BDBA779 Q24564024-799A37C3-6126-426A-B209-3B452D05706A Q26471909-F11773C0-16EF-4865-A89E-96E9003FFE9D Q26738385-6DF9F555-E791-4B18-A13C-5B1368C3DD57 Q26738986-4B490718-7A1F-4189-98A2-B50AF4470218 Q26740529-B7B82660-B397-47F0-92D7-A611745F1972 Q26740988-673DE994-40C1-47C4-80BA-DF58529B41C2 Q26741009-C9879E24-589C-4030-A94A-32529B7C2D00 Q26744076-D5167B37-A094-4BED-A56F-50FEEA8327BD Q26744284-F2839C1A-C551-413F-97C4-2B4A23728F72 Q26744339-974F2A96-4D8B-4BA7-9598-D18B9D8DCD91 Q26745427-AB73DBA6-E485-486E-9657-9C400455B3F7 Q26745776-B6A5DEC7-54F6-4B4D-8151-E62B9209688E Q26747276-49434660-753E-4DF9-937F-EC2A61488E05 Q26748851-65CF2B05-7A84-463E-BCA0-D8B790EE9710 Q26749005-9AF2D2C6-E376-4899-B06A-AF0369734ACE Q26775379-9C2B5049-6396-4FB8-B4A4-120EA8BA06B4 Q26775385-4E272AF0-0C8D-491F-8EAC-C900DFE8AB45 Q26775388-CA19F211-D6AC-4A5D-9A15-A9E07ED9A96E Q26775392-E2DBD4DE-E65A-4848-A150-524B107E5A0D Q26775394-B8E12D8C-A262-4022-B6C2-3FDF292FD15C Q26775396-494263CF-CA62-43E2-B192-E48A34FB177E Q26775603-7BFBE47C-93D3-4353-8769-96172153AFB1 Q26775677-B0000AD0-52D3-4CE6-A9CB-CD50553A5539 Q26778318-EEC046FF-E3D5-43AE-8BD7-CD1E5404B6BF Q26781159-9E15D5DA-EA83-4AF8-AEA1-CF4A6A9374B5 Q26781810-80266461-D3CB-4ED4-B6C0-D6E3D8743158 Q26784085-D518E4BE-4335-48FD-A234-68FA79865405 Q26784298-6D256050-F73A-4F5F-A7A8-59B919CD7A53 Q26786243-9F3E028E-7DD8-4C63-8EEF-A1EA32150C48 Q26786580-D0212C36-F827-4A63-86A9-21EFDFA345BF Q26786932-E78859D0-9327-454F-AAE1-53E77F3B773E Q26795555-20D7DE2B-34EE-43BF-936A-4D0D7CC248AC Q26795556-FE49E693-61F2-4FDC-AE15-81A52B10BDE2 Q26797297-6E174B28-A69C-46E9-AA66-F2CCC5505167 Q26799390-D47D69E6-3AA3-4444-AD6D-2E106067D416 Q26799467-918372B5-3D04-4CC6-9CB7-1CF544DA8E30 Q26800148-0E4415D2-1F34-43FF-8DDF-97FFB0337664 Q26800833-06905E2A-CA4F-48F4-B2D2-F2A0C37EE93E Q26824536-A9E1FCB6-4F32-4A6D-B6B1-071D7957FBDD

P2860

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

http://www.wikidata.org/entity/Q27852408

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase III study of afatinib or ...... carcinoma with EGFR mutations.

@ast

Phase III study of afatinib or ...... carcinoma with EGFR mutations.

@en

Phase III study of afatinib or ...... carcinoma with EGFR mutations.

@nl

type

label

Phase III study of afatinib or ...... carcinoma with EGFR mutations.

@ast

Phase III study of afatinib or ...... carcinoma with EGFR mutations.

@en

Phase III study of afatinib or ...... carcinoma with EGFR mutations.

@nl

prefLabel

Phase III study of afatinib or ...... carcinoma with EGFR mutations.

@ast

Phase III study of afatinib or ...... carcinoma with EGFR mutations.

@en

Phase III study of afatinib or ...... carcinoma with EGFR mutations.

@nl

P1433

Q27852408-7F653D50-EC90-4D76-8C53-A05A9D6F1452

P1476

Q27852408-0455448D-AEB5-43A5-ADF4-6D17CD02C1D7

P2093

Q27852408-06CF2969-0833-47C7-BB63-A9A22C7A7CE9

Q27852408-112EC2C0-E0DA-4540-92F6-DEE6C164FFCF

Q27852408-12790B30-EC1B-4C29-805B-6273F614D2C8

Q27852408-2888AA2A-4BD3-4736-84C9-6E4A9889AF59

Q27852408-34170A23-8FC5-4C32-9F8A-12E50D4808EB

Q27852408-377162AD-D236-4F1C-8BBA-4FF542B076A0

Q27852408-4663F851-4B4D-4A68-B5E6-1CD0958D36B8

Q27852408-515873A6-7E94-4B71-97D2-ED03D4DAFC73

Q27852408-5FDDD7F8-B167-4AA3-9A58-4C7A7B56F5FD

Q27852408-632F2B58-C57D-4FF4-9376-C3F06032FB55

P304

Q27852408-506D308F-EC29-4059-9C9B-F6488670AC71

P31

Q27852408-009D4B52-1EB5-4501-A383-29249253ECDE

P3181

Q27852408-F95646A6-BFDF-4953-8447-3D23E8B91E04

P356

Q27852408-3E36CD8B-B15E-4D03-B9CF-D84CC9325E64

P407

Q27852408-9FA6773B-A036-439A-B237-F09E61799B45

P433

Q27852408-FCC8419B-0D5A-47B3-A935-92A799957036

P478

Q27852408-FB98AEE5-736A-4DA7-978F-043DED03D26E

P50

Q27852408-0B8C90E2-6151-4797-93AB-EEFEE6CDB739

Q27852408-6458D691-1EAE-4960-BDA2-2720E8751D3D

Q27852408-9C98EE7A-E926-42A2-B08B-6F2C99FCF50D

Q27852408-BE619FE8-395F-442C-819F-77D2AB3FD810

Q27852408-ED1A1E06-06C8-4614-B98F-36320A251C5B

P577

Q27852408-169F87E1-AAB1-46A2-8AFF-C9BB27AD110C

P698

Q27852408-9F0D7244-C45A-4499-AA23-89FBEDCEB0E4

P921

Q27852408-1B38B05D-2B5D-4605-A354-598C47075ADA

Q27852408-A448E5E6-CC4F-4900-A0DD-C179912C1787

P3181

P356

JCO.2012.44.2806

P1433

Journal of Clinical Oncology

P1476

Phase III study of afatinib or ...... ocarcinoma with EGFR mutations

@en

P2093

Chun-Ming Tsai

http://www.w3.org/2001/XMLSchema#string

Dan Massey

http://www.w3.org/2001/XMLSchema#string

Jaafar Bennouna

http://www.w3.org/2001/XMLSchema#string

Kenneth O'Byrne

http://www.w3.org/2001/XMLSchema#string

Ki Hyeong Lee

http://www.w3.org/2001/XMLSchema#string

Lecia V Sequist

http://www.w3.org/2001/XMLSchema#string

Martin Schuler

http://www.w3.org/2001/XMLSchema#string

Mehdi Shahidi

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Yamamoto

http://www.w3.org/2001/XMLSchema#string

Riyaz Shah

http://www.w3.org/2001/XMLSchema#string

P304

3327-3334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

559932

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2012.44.2806

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

James Chih-Hsin Yang

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23816960

http://www.w3.org/2001/XMLSchema#string

P921